Nilgün ALTIN, Burak UFLAZ, Mehmet DENİZAYLI, Bahar BEKTAN, İrfan ŞENCAN, Salih CESUR

Ertapenem tedavisine bağlı epileptik nöbet gelişen, santral sinir sistemi hastalığı olmayan kronik böbrek yetmezliği hastası

Karbapenem grubu antibiyotikler (imipenem, meropenem, ertapenem,doripenem ) diğer beta-laktam antibiyotikler gibi örotoksik potansiyele sahiptir. Tüm beta-laktam antibiotikler yüksek konsantrasyonda nöbet gelişimine neden olabilir. Karbapenem grubu antibiyotiklerin nörotoksik yan etkilerinin gamma amino bütirik asit (GABA) reseptörleri ile etkileşim sonucu geliştiği sanılmaktadır. Bu makalede, kronik böbrek yetmezliği olan , santral sinir sistemi hastalığı olmayan, ertapenem tedavisi esnasında epileptik nöbet gelişen 61 yaşında bir erkek hasta sunuldu. Literatürdeki benzer olgular tartışıldı. Kronik böbrek yetmezliği olan hastalarda ertapenem tedavisi başlananırken, klinisyen ertapenem tedavisine bağlı epileptik nöbet gelişebileceğini akılda tutmalıdır.

Seizures in a patient with chronic renal failure without central neural system disorder due to ertapenem treatment

Carbapenem group antibiotics (imipenem, meropenem, ertapenem and doripenem) have a neurotoxic potential such as other beta-lactam antibiotics. All beta-lactam antibiotics in high concentration can causes seizures. Neurotoxicity of carbapenem group antibiotics seems to be caused by an interaction of gammaamino butyric acid (GABA) reseptors. In this article, a 61 years old male patient with chronic renal failure and without central nevous system disease in whom seizure developed during ertapenem treatment was presented. Similar cases in the literature were discussed. Clinicians should bear in mind the fact that epileptic seizure associated with ertapenem treatment may develop when initiating ertapenem treatment.

PDF

___

1.The Sanford guide to Antimicrabial Therapy . Gilbert DN, moellering RC, Eliopoulos GM, Chambers HF, Saag MS (eds),USA. 2010, p: 84-91.
2. Şenol E. Karbapenemlerin yeni açılımları. ANKEM Dergisi 2009; 23 (Ek 2):14-16.
3. Işık F, Arslan U, Tuncer İ. Kan kültürlerinden izole edilen Klebsiella pneumoniae suşlarında genişlemiş spektrumlu beta-laktamaz varlığı ve antibiyotik duyarlılıkları. Mikrobiyol Bül., 2008; 42:131-136.
4. Norrby SR. Carbapenems in serious infections: a risk-benefit assessment. Drug Saf. 2000; 22:191-4.
5. Calandra GB, Wang c, aziz M, Brown KR. The safety profile of imipenem/ silastatin: worldwide clinical experience based on 3470 patients. J Antimicrobial Chemother 1986; 18 Suppl E:193-202.
6. Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrobial Chemotherapy; 2000; 45:5-7.
7. Duquaine S, Kitchell E, Tate T, Tannen RC, Wickremasinghe IM. Central Nervous System Toxicity Associated with Ertapenem Use. Ann Pharmacother. 2010. (Epub ahead of print).(Abstract).
8. Liao FF, Huang YB, Chen CY. Decrease in serum valproic acid levels during treatment with ertapenem. Am J Health Syst Pharm. 2010; 67:1260-4.
9. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis. 2009; 49 : 291-8.
10. Ong C, Chua AC, Tambyah PA, Fei YS. Seizerius associated with ertapenem. In j Antimicrobial Agents. 2008;31:290.
11. Tobin JK, Golightly LK, Kick SD, Jones MA. Valproic acidcarbapenem interaction: report of six cases and a review of the literature. Drug Metabol Drug Interact. 2009; 24 :153-82.
12. Fica AE, Abusada NJ. Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency. Scand J Infect Dis. 2008;40: 983-5.
13. Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy. 2007 ;27 :1202-5.
14. Saidel-Odes L, Borer A, Riesenberg K, Smolyakov R, Schlaeffer F. History of cerebrovascular events: a relative contraindication to ertapenem treatment. Clin Infect Dis. 2006; 15;43 :262-3.
15. Seto AH, Song JC, Guest SS. Ertapenem-associated seizures in a peritoneal dialysis patient. Ann Pharmacother. 2005 ;39 :352-6.
16. Winston DJ, Lazarus HM, Beveridge RA, Hathorn JW, Gucalp R, Ramphal R, et al.Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis. 2001 ;32 :381-90.
17. Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011;31:408-23.
18. Ertapenem (İnvanz® ) ilaç prospektüs bilgileri.www.iegm.gov.tr/ Folders.